Editorial: preclinical data reproducibility for R&D - the challenge for neuroscience
详细信息 查看全文
- 作者：Thomas Steckler
- 刊名：SpringerPlus
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：4
- 期：1
- 全文大小：226KB
- 参考文献：Anderson DC, Kodukula K: Biomarkers in pharmacology and drug discovery. Biochem Pharmacol 2014, 87:172鈥?88. 10.1016/j.bcp.2013.08.026CrossRef
Begley CG, Ellis LM: Drug development: raise standards for preclinical cancer research. Nature 2012, 483:531鈥?33. 10.1038/483531aCrossRef
Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafo MR: Power failure: why small sample size undermines the reliability of neuroscience. Nature Rev Neurosci 2013, 14:365鈥?76. 10.1038/nrn3475CrossRef
Chalmers I, Glasziou P: Avoidable waste in the production and reporting of research evidence. Lancet 2009, 374:86鈥?9. 10.1016/S0140-6736(09)60329-9CrossRef
Cyranoski D: China drugs head fired over article row. Nature 2013, 498:283. 10.1038/498283aCrossRef
Fanelli D: How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. PLoS ONE 2009, 4:e5738. 10.1371/journal.pone.0005738CrossRef
Fang FC, Steen RG, Casadevall A: Misconduct accounts for the majority of retracted publications. Proc Natl Acad Sci USA 2012, 109:17028鈥?7033. 10.1073/pnas.1212247109CrossRef
Fitz NF, Cronican AA, Lefterov I, Koldamova R: Comment on 鈥淎poE-directed therapeutics rapidly clear 尾-amyloid and reverse deficits in AD mouse models鈥? Science 2013, 340:924.CrossRef
Franco A, Malhotra N, Simonovits G: Publication bias in the social sciences: unlocking the file drawer. Science 2014, 345:1502鈥?505. 10.1126/science.1255484CrossRef
Frantz S: Therapeutic area influences drug development costs. Nature Rev Drug Disc 2004, 3:466鈥?67.CrossRef
Ioannidis JPA: Why most published research findings are false. PLoS Med 2005, 2:e124. 10.1371/journal.pmed.0020124CrossRef
Ioannidis JPA: How to make more published research true. PLoS Med 2014, 11:e1001747. 10.1371/journal.pmed.1001747CrossRef
Kilkenny C, Parsons N, Kadyszewski E, Festing MFW, Cuthill IC, Fry D, Hutton J, Altman DG: Survey of the quality of experimental design, statistical analysis and experimental reporting of research using animals. PLoS ONE 2009, 11:e7824.CrossRef
Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Disc 2004, 3:711鈥?15. 10.1038/nrd1470CrossRef
Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD: A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012, 490:187鈥?91. 10.1038/nature11556CrossRef
Lazzeroni LC, Lu Y, Belitskaya-Levy I: P-values in genomics: apparent precision masks high uncertainty. Mol Psychiatry 2014. doi:10.1038/mp.2013.184
Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, Al-Shahi Salman R, Khan AW, Glasziou P: Biomedical research: increasing value, reducing waste. Lancet 2014, 383:101鈥?04. 10.1016/S0140-6736(13)62329-6CrossRef
McNutt M: Journals unite for reproducibility. Science 2014, 346:678.
Mehta J: Preclinical Outsourcing Report: Long-Term and more Collaborative Contracts to Optimize Cost Structures. Contract Pharma; 2011. http://鈥媤ww.鈥媍ontractpharma.鈥媍om/鈥媔ssues/鈥?011芒鈧€?9/鈥媣iew_鈥媐eatures/鈥媝reclinical-outsourcing-report/鈥?/span>
Michalek AM, Hutson AD, Wicher CP, Trump DL: The costs and underappreciated consequences of research misconduct: a case study. PLoS Med 2010, 7:e1000318. 10.1371/journal.pmed.1000318CrossRef
Mobley A, Linder SK, Braeuer R, Ellis LM, Zwelling L: A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic. PLoS ONE 2013, 8:e63221. 10.1371/journal.pone.0063221CrossRef
Moris F, Shackelford B: Extramural R&D Funding by U.S.-Located Businesses Nears $30 Billion in 2011. InfoBrief, NSF; 2014:14鈥?14. http://鈥媤ww.鈥媙sf.鈥媑ov/鈥媠tatistics/鈥媔nfbrief/鈥媙sf14314/鈥媙sf14314.鈥媝df
Motulsky HJ: Common misconceptions about data analysis and statistics. Naunys Schmiedebergs Arch Pharmacol 2014. doi:10.1007/s00210鈥?14鈥?037鈥?
Nature Editorial: Reducing our irreproducibility. Nature 2013, 496:398. (go.nature.com/oloeip)CrossRef
Nature Editorial: Journals unite for reproducibility. Nature 2014, 515:7.
Nature Medicine Opinions: The yearbook. Nature Med 2013, 19:1561.CrossRef
Normile D: Rieken shrinks troubled center. Science 2014, 345:1110. 10.1126/science.345.6201.1110CrossRef
Nuzzo R: Statistical errors. Nature 2014, 506:150鈥?52. 10.1038/506150aCrossRef
O鈥橞oyle EH Jr, Banks GC, Gonzalez-Mule E: The chrysalis effect: how ugly initial results metamorphosize into beautiful articles. J Manage 2014. doi:10.1177/0149206314527133
Peers IS, Ceuppens PR, Harbron C: In search of preclinical robustness. Nature Rev Drug Disc 2012, 11:733鈥?34. 10.1038/nrd3849CrossRef
Peers IS, South MC, Ceuppens PR, Bright JD, Pilling E: Can you trust your animal study data? Nature Rev Drug Disc 2014, 13:560.CrossRef
Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DA, Golde TE, Felsenstein KM: Comment on 鈥淎poE-directed therapeutics rapidly clear 尾-amyloid and reverse deficits in AD mouse models鈥? Science 2013, 340:924.CrossRef
Prinz F, Schlange T, Asadullah K: Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Disc 2011, 10:712. 10.1038/nrd3439-c1CrossRef
Schooler JW: Metascience could rescue the 鈥榬eplication crisis鈥? Nature 2014, 515:9. 10.1038/515009aCrossRef
Selyukh A, Yukhananov A: FDA finds U.S. drug research firm faked documents. Reuters; 2011. http://鈥媢k.鈥媟euters.鈥媍om/鈥媋rticle/鈥?011/鈥?7/鈥?6/鈥媓ealth-us-fda-cetero-violation-idUKTRE76P7E3201鈥?0726
Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D鈥橦ooge R, De Strooper B: Comment on 鈥淎poE-directed therapeutics rapidly clear 尾-amyloid and reverse deficits in AD mouse models鈥? Science 2013, 340:924.CrossRef
The Economist: Unreliable research: trouble at the lab. Economist 2013, 19th:26鈥?0.
Tsilidis KK, Panagiotou OA, Sena ES, Aretoula E, Evangelou E, Howells DW, Salman RA-S, Macleod MR, Ioannidis JPA: Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol 2013, 11:e1001609. 10.1371/journal.pbio.1001609CrossRef
Van Noorden R: The trouble with retractions. Nature 2011, 478:26鈥?8. 10.1038/478026aCrossRef
Van Noorden R: Irish university labs face external audits. Nature 2014, 510:325. 10.1038/510325aCrossRef
Vasilevsky NA, Brush MH, Paddock H, Ponting L, Tripathy SJ, LaRocca GM, Haendel MA: On the reproducibility of science: unique identification of research resources in the biomedical literature. PeerJ 2013, 1:e148.CrossRef
Wahlsten D: Standardizing tests of mouse behavior: reasons, recommendations, and reality. Physiol Behav 2001, 73:695鈥?04. 10.1016/S0031-9384(01)00527-3CrossRef
Wahlsten D, Rustay NR, Metten P, Crabbe JC: In search of a better mouse test. Trends Neurosci 2003, 26:132鈥?36. 10.1016/S0166-2236(03)00033-XCrossRef
Wellcome Trust: Wellcome Trust Grant Conditions. 2013. - 作者单位：Thomas Steckler (19)
19. Janssen Research & Development, Turnhoutseweg 30, 2340, Beerse, Belgium - 刊物类别：Science, general;
- 刊物主题：Science, general;
- 出版者：Springer International Publishing
- ISSN：2193-1801
文摘